Literature DB >> 7809029

Multimerization behaviour of single chain Fv variants for the tumour-binding antibody B72.3.

D Desplancq1, D J King, A D Lawson, A Mountain.   

Abstract

A systematic study has been performed on the relationship between linker length, relative orientation of variable domains, multimerization behaviour and antigen binding activity for single chain Fvs (scFvs) of the tumour-binding antibody B72.3. Thirteen scFv variants with linkers comprising up to six repeats of the motif Gly-Gly-Gly-Gly-Ser were studied. All these scFvs showed a tendency to form dimers or higher molecular weight species, and this tendency decreased with increasing linker length. The dimers and higher molecular weight forms may arise from head to tail intermolecular association of VH and VL domains. For each linker length, scFvs with the organization VL-linker-VH showed greater binding activity than those with the organization VH-linker-VL. In fact, for the latter organization only the variant with a 30 amino acid linker showed good binding activity, suggesting that (i) for B72.3 the C-terminus of VH or the N-terminus of VL makes a structural contribution to antigen binding, and (ii) shorter linkers interfere with this contribution. Antigen binding studies on scFvs should be interpreted with caution because of their tendency to multimerize. Such multimerization can be minimized by using linkers longer than those in common use.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7809029     DOI: 10.1093/protein/7.8.1027

Source DB:  PubMed          Journal:  Protein Eng        ISSN: 0269-2139


  18 in total

Review 1.  Antibody vectors for imaging.

Authors:  Tove Olafsen; Anna M Wu
Journal:  Semin Nucl Med       Date:  2010-05       Impact factor: 4.446

2.  High resolution NMR-based model for the structure of a scFv-IL-1beta complex: potential for NMR as a key tool in therapeutic antibody design and development.

Authors:  Ian C Wilkinson; Catherine J Hall; Vaclav Veverka; Jiye Y Shi; Frederick W Muskett; Paul E Stephens; Richard J Taylor; Alistair J Henry; Mark D Carr
Journal:  J Biol Chem       Date:  2009-09-23       Impact factor: 5.157

3.  Expression and purification strategies for the production of single-chain antibody and T-cell receptor fragments in E. coli.

Authors:  P E Molloy; B M Graham; P M Cupit; S D Grant; A J Porter; C Cunningham
Journal:  Mol Biotechnol       Date:  1995-12       Impact factor: 2.695

4.  Functional expression of a single-chain antibody fragment against human epidermal growth factor receptor 2 (HER2) in Escherichia coli.

Authors:  Vajihe Akbari; Hamid Mir Mohammad Sadeghi; Abbas Jafrian-Dehkordi; Daryoush Abedi; C Perry Chou
Journal:  J Ind Microbiol Biotechnol       Date:  2014-03-27       Impact factor: 3.346

5.  Linker engineering in anti-TAG-72 antibody fragments optimizes biophysical properties, serum half-life, and high-specificity tumor imaging.

Authors:  Nicholas E Long; Brandon J Sullivan; Haiming Ding; Stephanie Doll; Michael A Ryan; Charles L Hitchcock; Edward W Martin; Krishan Kumar; Michael F Tweedle; Thomas J Magliery
Journal:  J Biol Chem       Date:  2018-04-18       Impact factor: 5.157

6.  Enhanced bovine herpesvirus type 1 neutralization by multimerized single-chain variable antibody fragments regardless of differential glycosylation.

Authors:  Yfke Pasman; Eva Nagy; Azad K Kaushik
Journal:  Clin Vaccine Immunol       Date:  2012-06-13

7.  Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR.

Authors:  Jennifer S Michaelson; Stephen J Demarest; Brian Miller; Aldo Amatucci; William B Snyder; Xiufeng Wu; Flora Huang; Samantha Phan; Sharon Gao; Adam Doern; Graham K Farrington; Alexey Lugovskoy; Ingrid Joseph; Veronique Bailly; Xin Wang; Ellen Garber; Jeff Browning; Scott M Glaser
Journal:  MAbs       Date:  2009-03-11       Impact factor: 5.857

8.  Basis for selection of improved carbohydrate-binding single-chain antibodies from synthetic gene libraries.

Authors:  S J Deng; C R MacKenzie; T Hirama; R Brousseau; T L Lowary; N M Young; D R Bundle; S A Narang
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

Review 9.  Engineering T cells for immunotherapy of primary human hepatocellular carcinoma.

Authors:  Leidy D Caraballo Galva; Lun Cai; Yanxia Shao; Yukai He
Journal:  J Genet Genomics       Date:  2020-01-28       Impact factor: 4.275

10.  The efficacy of NP11-4-derived immunotoxin scFv-artesunate in reducing hepatic fibrosis induced by Schistosoma japonicum in mice.

Authors:  Hong Li; Chunyan Gu; Yongya Ren; Yang Dai; Xiaojuan Zhu; Jing Xu; Yuhua Li; Zhenning Qiu; Jin Zhu; Yinchang Zhu; Xiaohong Guan; Zhenqing Feng
Journal:  J Biomed Res       Date:  2011-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.